Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2017-03-06 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
Asthma Fully Enrolled
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science SA, a pharmaceutical company, dated March 6, 2017. It announces the completion of patient recruitment for a Phase 3 study (AB07015) in severe asthma and the initiation of a new Phase 3 study (AB14001). It details the status of clinical trials, intellectual property, and provides background on the drug masitinib and the company. This content strongly aligns with an announcement providing updates on ongoing research, development, and business operations, which is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on clinical trial milestones and operational updates rather than comprehensive financial results (like a 10-K or IR), and it is a formal announcement, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS). Given the nature of clinical trial updates, which often accompany or substitute for quarterly financial highlights, ER is a strong candidate, but RNS is the most appropriate fallback for specific operational announcements not covered by other codes. However, many companies use press releases detailing operational milestones like this as their primary means of communicating key business updates, which often overlap with the function of an Earnings Release (ER) or Investor Presentation (IP). Since it is a formal announcement of operational progress (recruitment completion, new study initiation) rather than a full financial statement or a presentation deck, and it is not a short notice about a report, I will classify it as an Earnings Release (ER) as it communicates key performance indicators (trial progress) for the period, or RNS if ER is too specific. Given the focus on trial progress, which is often a key metric discussed during earnings, ER is plausible, but RNS covers general regulatory/operational announcements well. Let's re-evaluate against the definitions. It is not a CT, 10-K, AR, or IR. It is not a DIV or NAV. It is a press release detailing operational progress. This type of announcement is often categorized as an ER if it's near a reporting date, or RNS otherwise. Since it's a standalone operational update, RNS is the safest general classification for non-standard filings, but ER often captures these operational highlights. Given the context of financial reporting databases, operational updates like this are frequently grouped with ERs. I will lean towards RNS as the most accurate general regulatory announcement category for this specific type of clinical trial update press release, as it doesn't contain the actual financial results summary typical of an ER.
2017-03-06 English
CPFR
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces the 'Émission d'actions nouvelles' (Issuance of new shares) under the heading 'Ligne de capital' (Capital line). It details the number of shares issued (520,091), the price (€14.62), and confirms the funds raised will be used for company investments. This action directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because it is a specific announcement about a financing event, nor is it a share repurchase (POS) as it is an issuance of *new* shares to raise capital.
2017-01-13 French
CPEng
Regulatory Filings Classification · 1% confidence The document is an announcement from AB Science dated January 9, 2017, detailing the publication of Phase 3 clinical trial results for masitinib in 'The Lancet', a medical journal. It summarizes the key efficacy and safety findings (primary endpoint 4R75%, subgroup analysis, etc.) and includes quotes from experts and the CEO regarding the significance of the publication. This is not a formal regulatory filing like a 10-K or an IR, nor is it a transcript (CT) or a general earnings release (ER). It is a specific announcement about clinical trial data being published in a scientific journal, which is best classified as a general announcement or regulatory filing that doesn't fit the specific financial report categories. Given the content focuses on clinical trial results and their publication, it most closely aligns with a general regulatory announcement or a specific type of disclosure that doesn't map perfectly to the financial codes. However, since it is a press release announcing a significant scientific/clinical development, and not a standard financial report, the closest fit among the provided options that covers general announcements or specific non-financial disclosures is 'Regulatory Filings' (RNS) as a catch-all for important, non-standard disclosures, or potentially 'LTR' if the trial results were mandated by a legal/regulatory body, but RNS is safer for general press releases about scientific milestones. Since the document is substantial (over 10,000 characters) and contains the full substance of the announcement, it is not an RPA (Report Publication Announcement). I will classify it as RNS as it is a significant, non-standard regulatory/corporate announcement.
2017-01-09 English
CPFR
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing that the results of their Phase 3 clinical trial for masitinib in treating systemic mastocytosis have been published in the medical journal *The Lancet*. This is not the full financial report (10-K), an interim report (IR), or a standard earnings release (ER). It is an announcement detailing a significant event related to product development and clinical validation, which often accompanies or precedes regulatory filings or investor updates. Since it is a formal announcement detailing scientific progress and citing a prestigious publication, it fits best under a general regulatory/corporate announcement category. Given the options, it is a specific corporate announcement about a scientific/clinical milestone. While it is not a standard financial filing, it is a formal communication to the market about a key development. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a pure earnings release (ER). It is an announcement of a scientific finding, which often falls under general regulatory disclosures or investor relations material. Since it is a formal press release announcing a major scientific publication, and it doesn't fit the specific financial/governance codes, the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), or potentially Investor Presentation (IP) if it were structured as a deck, but here it functions as a formal news release about a published study. Given the context of a pharmaceutical company announcing peer-reviewed trial results, this is a critical piece of information for investors, but it is primarily a scientific/regulatory update. I will classify it as RNS as a broad regulatory/corporate announcement, as it is not a standard financial report or a specific management/governance document.
2017-01-09 French
CPEng
Regulatory Filings Classification · 1% confidence The document is a press release dated January 3, 2017, announcing new preclinical data regarding the drug masitinib for ALS. It details scientific findings, references previous results, quotes a professor, and includes standard sections like 'About Amyotrophic Lateral Sclerosis', 'About masitinib', 'About AB Science', and 'Forward-looking Statements'. This format is characteristic of an initial announcement of scientific or clinical progress, often released to the public before a formal, comprehensive report (like a 10-K or IR) or a detailed investor presentation (IP). Since it is an initial announcement of results/data, it fits best under 'Earnings Release' (ER) if it were financial results, but since it is scientific/development news, it is most closely aligned with an 'Earnings Release' (ER) in terms of being a timely, high-level announcement of key developments, or potentially a general 'Regulatory Filing' (RNS) if no other category fits. Given the focus on presenting new data/findings, it functions similarly to an ER for a biotech company, announcing a key milestone. However, none of the definitions perfectly capture a scientific data announcement. It is not a Call Transcript (CT), Investor Presentation (IP), or Management Discussion (MDA). Since it is a press release announcing key developments, and not a formal financial report, 'ER' (Earnings Release) is often used as the closest proxy for a major, timely company announcement, even if the content is scientific rather than purely financial results. Given the options, and recognizing this is a news announcement about R&D progress, 'ER' is the most appropriate fit for a high-impact, non-statutory announcement.
2017-01-03 English
CPFR
Regulatory Filings Classification · 1% confidence The document is a press release dated January 3, 2017, from the pharmaceutical company AB Science SA. It announces new preclinical data regarding the drug masitinib's protective effect in Amyotrophic Lateral Sclerosis (ALS), referencing presentations at a scientific conference (27th International ALS/MND Symposium) and citing previous clinical/preclinical results and references. This format—a formal announcement detailing scientific/clinical progress, often referencing presentations or interim results—is characteristic of an Earnings Release (ER) or a general press release related to operational/research updates. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy (PSI), it best fits the 'Earnings Release' category, which often encompasses key operational and scientific updates released periodically, even if not strictly quarterly earnings figures. Given the focus on scientific data presentation at a conference, it is a primary communication of recent developments to the market, aligning most closely with ER, although it could also be considered RNS if no other category fit. However, ER is used for major periodic announcements, and scientific breakthroughs are key announcements for a biotech firm. The length (9821 chars) suggests it is a substantive announcement, not just a brief RPA.
2017-01-03 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.